Patient characteristics | LaC–taking patients, n = 42 | Control dialysis patients, n = 42 | Odds ratio (95% CI) | p value |
---|---|---|---|---|
Male sex, n (%) | 15 (35.7%) | 20 (47.6%) | 0.61 (0.25–1.47) | 0.269 |
Age, median (range) | 68 (45–83) | 70 (35–86) | – | 0.400 |
Gastric mucosal atrophy (mild, medium, severe)*, n (%) | 12 (28.6%), 10 (23.8%) 20 (47.6%) | 14 (33.3%), 10 (23.8%), 18 (42.9%) | – | 0.879 |
Primary diseases of dialysis (diabetes, hypertension, nephritis), n (%) | 18 (42.9%), 5 (11.9%), 19 (45.2%) | 13 (31.0%), 7 (16.7%), 22 (52.4%) | – | 0.507 |
Years since start of dialysis, median (range) | 6.12 (0.7–26.4) | 3.58 (0.002–12.5) | – | 0.0002 |
Ca, mg/dL, median (range) | 8.75 (7.2–10.2) | 8.9 (6.1–10.3) | – | 0.300 |
IP, mg/dL, median (range) | 5.5 (3.1–8.3) | 4.9 (1.9–7.5) | – | 0.320 |
TP, g/dL, median (range) | 6.4 (4.3–7.9) | 6.6 (3.9–7.9) | – | 0.184 |
Albumin, g/dL, median (range) | 3.5 (2.4–4.0) | 3.5 (2.5–4.7) | – | 0.362 |
Total cholesterol, mg/dL, median (range) | 158.5 (88–240) | 160 (93–303) | – | 0.402 |
HDL–cholesterol, mg/dL, median (range) | 47 (18–97) | 49.5 (23–78) | – | 0.601 |
Triglyceride, mg/dL, median (range) | 97 (35–336) | 92.5 (36–271) | – | 0.721 |
WBC, /µL, median (range) | 5720 (2650–12,470) | 5210 (2800–11,800) | – | 0.068 |
Hemoglobin, g/dL, median (range) | 10.5 (7.3–12.8) | 10.6 (7.1–12.4) | – | 0.709 |
NSAIDs (including low–dose aspirin), n (%) | 18 (42.9%) | 10 (23.8%) | 2.4 (0.94–6.12) | 0.064 |
PPIs, n (%) | 34 (81.0%) | 32 (76.2%) | 1.32 (0.47–3.79) | 0.595 |
PPIs + H2RA, n (%) | 38 (90.5%) | 35 (83.3%) | 1.9 (0.51–7.05) | 0.332 |
Gastric mucoprotective drugs, n (%) | 13 (31.0%) | 6 (14.3%) | 2.79 (0.91–7.95) | 0.068 |